Answer
Exposure to both components can increase with renal or hepatic impairment. The selected product is contraindicated in moderate or severe hepatic impairment, while renal impairment and mild hepatic impairment require caution and clinical monitoring.
Sources for this answer
- Targinact 5 mg/2.5 mg prolonged-release tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.